Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226350085> ?p ?o ?g. }
- W4226350085 abstract "Non-small cell lung cancer (NSCLC) is the most common lung cancer, accounting for approximately 80% to 85% of all cases. For people with localised NSCLC (stages I to III), it has been speculated that immunotherapy may be helpful for reducing postoperative recurrence rates, or improving the clinical outcomes of current treatment for unresectable tumours. This is an update of a Cochrane Review first published in 2017 and it includes two new randomised controlled trials (RCTs).To assess the effectiveness and safety of immunotherapy (excluding checkpoint inhibitors) among people with localised NSCLC of stages I to III who received curative intent of radiotherapy or surgery.We searched the following databases (from inception to 19 May 2021): CENTRAL, MEDLINE, Embase, CINAHL, and five trial registers. We also searched conference proceedings and reference lists of included trials.We included RCTs conducted in adults (≥ 18 years) diagnosed with NSCLC stage I to III after surgical resection, and those with unresectable locally advanced stage III NSCLC receiving radiotherapy with curative intent. We included participants who underwent primary surgical treatment, postoperative radiotherapy or chemoradiotherapy if the same strategy was provided for both intervention and control groups.Two review authors independently selected eligible trials, assessed risk of bias, and extracted data. We used survival analysis to pool time-to-event data, using hazard ratios (HRs). We used risk ratios (RRs) for dichotomous data, and mean differences (MDs) for continuous data, with 95% confidence intervals (CIs). Due to clinical heterogeneity (immunotherapeutic agents with different underlying mechanisms), we combined data by applying random-effects models.We included 11 RCTs involving 5128 participants (this included 2 new trials with 188 participants since the last search dated 20 January 2017). Participants who underwent surgical resection or received curative radiotherapy were randomised to either an immunotherapy group or a control group. The immunological interventions were active immunotherapy Bacillus Calmette-Guérin (BCG) adoptive cell transfer (i.e. transfer factor (TF), tumour-infiltrating lymphocytes (TIL), dendritic cell/cytokine-induced killer (DC/CIK), antigen-specific cancer vaccines (melanoma-associated antigen 3 (MAGE-A3) and L-BLP25), and targeted natural killer (NK) cells. Seven trials were at high risk of bias for at least one of the risk of bias domains. Three trials were at low risk of bias across all domains and one small trial was at unclear risk of bias as it provided insufficient information. We included data from nine of the 11 trials in the meta-analyses involving 4863 participants. There was no evidence of a difference between the immunotherapy agents and the controls on any of the following outcomes: overall survival (HR 0.94, 95% CI 0.84 to 1.05; P = 0.27; 4 trials, 3848 participants; high-quality evidence), progression-free survival (HR 0.94, 95% CI 0.86 to 1.03; P = 0.19; moderate-quality evidence), adverse events (RR 1.12, 95% CI 0.97 to 1.28; P = 0.11; 4 trials, 4126 evaluated participants; low-quality evidence), and severe adverse events (RR 1.14, 95% CI 0.92 to 1.40; 6 trials, 4546 evaluated participants; low-quality evidence). Survival rates at different time points showed no evidence of a difference between immunotherapy agents and the controls. Survival rate at 1-year follow-up (RR 1.02, 95% CI 0.96 to 1.08; I2 = 57%; 7 trials, 4420 participants; low-quality evidence), 2-year follow-up (RR 1.02, 95% CI 0.93 to 1.12; 7 trials, 4420 participants; moderate-quality evidence), 3-year follow-up (RR 0.99, 95% CI 0.90 to 1.09; 7 trials, 4420 participants; I2 = 22%; moderate-quality evidence) and at 5-year follow-up (RR 0.98, 95% CI 0.86 to 1.12; I2 = 0%; 7 trials, 4389 participants; moderate-quality evidence). Only one trial reported overall response rates. Two trials provided health-related quality of life results with contradicting results. AUTHORS' CONCLUSIONS: Based on this updated review, the current literature does not provide evidence that suggests a survival benefit from adding immunotherapy (excluding checkpoint inhibitors) to conventional curative surgery or radiotherapy, for people with localised NSCLC (stages I to III). Several ongoing trials with immune checkpoints inhibitors (PD-1/PD-L1) might bring new insights into the role of immunotherapy for people with stages I to III NSCLC." @default.
- W4226350085 created "2022-05-05" @default.
- W4226350085 creator A5024792434 @default.
- W4226350085 creator A5035315901 @default.
- W4226350085 creator A5039868090 @default.
- W4226350085 creator A5043778832 @default.
- W4226350085 creator A5047815639 @default.
- W4226350085 creator A5066832333 @default.
- W4226350085 creator A5075151419 @default.
- W4226350085 creator A5081922458 @default.
- W4226350085 date "2021-12-06" @default.
- W4226350085 modified "2023-10-13" @default.
- W4226350085 title "Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent" @default.
- W4226350085 cites W1557862154 @default.
- W4226350085 cites W1702502468 @default.
- W4226350085 cites W1919153942 @default.
- W4226350085 cites W1968762811 @default.
- W4226350085 cites W1973731306 @default.
- W4226350085 cites W1979538859 @default.
- W4226350085 cites W1983061784 @default.
- W4226350085 cites W1984655584 @default.
- W4226350085 cites W1985594917 @default.
- W4226350085 cites W1993312546 @default.
- W4226350085 cites W1999014818 @default.
- W4226350085 cites W2010382665 @default.
- W4226350085 cites W2012744533 @default.
- W4226350085 cites W2018092044 @default.
- W4226350085 cites W2020322537 @default.
- W4226350085 cites W2029744149 @default.
- W4226350085 cites W2035698893 @default.
- W4226350085 cites W2038486814 @default.
- W4226350085 cites W2044835625 @default.
- W4226350085 cites W2054930937 @default.
- W4226350085 cites W2076060212 @default.
- W4226350085 cites W2089668462 @default.
- W4226350085 cites W2100158834 @default.
- W4226350085 cites W2128083415 @default.
- W4226350085 cites W2128973831 @default.
- W4226350085 cites W2135885240 @default.
- W4226350085 cites W2139248078 @default.
- W4226350085 cites W2140111836 @default.
- W4226350085 cites W2155464214 @default.
- W4226350085 cites W2156763707 @default.
- W4226350085 cites W2157245810 @default.
- W4226350085 cites W2159055213 @default.
- W4226350085 cites W2160834915 @default.
- W4226350085 cites W2166618121 @default.
- W4226350085 cites W2167571044 @default.
- W4226350085 cites W2168718800 @default.
- W4226350085 cites W2179066377 @default.
- W4226350085 cites W2344034377 @default.
- W4226350085 cites W2406751245 @default.
- W4226350085 cites W2473786944 @default.
- W4226350085 cites W2507737385 @default.
- W4226350085 cites W2560367415 @default.
- W4226350085 cites W2566863750 @default.
- W4226350085 cites W2567564314 @default.
- W4226350085 cites W2577269691 @default.
- W4226350085 cites W2585613986 @default.
- W4226350085 cites W2611460276 @default.
- W4226350085 cites W2753065806 @default.
- W4226350085 cites W2755243171 @default.
- W4226350085 cites W2761115034 @default.
- W4226350085 cites W2781978580 @default.
- W4226350085 cites W2807385394 @default.
- W4226350085 cites W2892229185 @default.
- W4226350085 cites W2978795816 @default.
- W4226350085 cites W2995072671 @default.
- W4226350085 cites W3022903699 @default.
- W4226350085 cites W3038640705 @default.
- W4226350085 cites W3082528698 @default.
- W4226350085 cites W4205947786 @default.
- W4226350085 cites W4231361596 @default.
- W4226350085 cites W4237716404 @default.
- W4226350085 cites W4255758041 @default.
- W4226350085 doi "https://doi.org/10.1002/14651858.cd011300.pub3" @default.
- W4226350085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34870327" @default.
- W4226350085 hasPublicationYear "2021" @default.
- W4226350085 type Work @default.
- W4226350085 citedByCount "6" @default.
- W4226350085 countsByYear W42263500852022 @default.
- W4226350085 countsByYear W42263500852023 @default.
- W4226350085 crossrefType "journal-article" @default.
- W4226350085 hasAuthorship W4226350085A5024792434 @default.
- W4226350085 hasAuthorship W4226350085A5035315901 @default.
- W4226350085 hasAuthorship W4226350085A5039868090 @default.
- W4226350085 hasAuthorship W4226350085A5043778832 @default.
- W4226350085 hasAuthorship W4226350085A5047815639 @default.
- W4226350085 hasAuthorship W4226350085A5066832333 @default.
- W4226350085 hasAuthorship W4226350085A5075151419 @default.
- W4226350085 hasAuthorship W4226350085A5081922458 @default.
- W4226350085 hasBestOaLocation W42263500852 @default.
- W4226350085 hasConcept C126322002 @default.
- W4226350085 hasConcept C141071460 @default.
- W4226350085 hasConcept C143998085 @default.
- W4226350085 hasConcept C146357865 @default.
- W4226350085 hasConcept C151730666 @default.
- W4226350085 hasConcept C168563851 @default.
- W4226350085 hasConcept C197934379 @default.
- W4226350085 hasConcept C207103383 @default.